France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables
France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables
Overview
France bioprocessing tech firm's H1 revenue rose 2.5%, or 6.4% in constant currencies
Underlying EBITDA for H1 increased 3.7%, margin rose to 31.4%
Company confirms 2026 guidance for sales revenue growth of 6-10% in constant currencies
Outlook
Sartorius Stedim Biotech expects 2026 sales revenue growth of 6% to 10% in constant currencies
Company says customer compensation for U.S. tariffs could reduce revenue by up to EUR 35 mln
Sartorius Stedim Biotech projects 2026 underlying EBITDA margin to increase to slightly above 31%
Result Drivers
RECURRING CONSUMABLES - Co said recurring business with consumables was the main driver of H1 growth across all regions
TARIFF REFUNDS - H1 results were influenced by U.S. tariff refunds and compensation to customers, which had a technical impact on reported revenue
ASIA/PACIFIC RECOVERY - Strong growth in Asia/Pacific region supported by continued recovery in China
Company press release: ID:nEQ52W4WYa
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
H1 Adjusted EBITDA |
| EUR 478.90 mln |
|
H1 Operating Income |
| EUR 303.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Sartorius Stedim Biotech SA is €227.50, about 29.8% above its July 22 closing price of €175.30
The stock recently traded at 31 times the next 12-month earnings vs. a P/E of 31 three months ago
Reuters Recommended Reads
July 22 - Switzerland's Lonza H1 sales rise, lifts FY core EBITDA margin forecast
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook
July 22 - Repligen beefs up cell therapy business with $1.5 billion deal for BioLife
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)